Form 4: Krystal Biotech Director Everett Rand Sutherland Awarded Stock Options

Director Everett Rand Sutherland of Krystal Biotech, Inc. was granted 5,000 stock options on June 30, 2024, vesting monthly over one year.

Summary

• Everett Rand Sutherland, a director of Krystal Biotech, Inc., was awarded 5,000 stock options on June 30, 2024.
• The options have an exercise price of $183.64.
• The options vest in equal monthly installments over a one-year period.
• The options expire on June 30, 2034.
• Following the transaction, Sutherland directly owns 5,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning director interests with shareholders, but it's not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotech companies.
• The vesting schedule of one year is relatively standard, encouraging continued service and alignment with company performance.
• Comparing the exercise price and the number of options granted to similar companies would provide a more comprehensive assessment of the grant's value.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to incentivize the director to increase shareholder value.
• Employees may see the grant as a positive sign of the company's commitment to its leadership.

Key Dates